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Abstract 
Glioblastoma (GBM) is the most common and aggressive type of gliomas in humans. It is also 
highly resistant to most treatment methods. Nearly 12,000 people are diagnosed with glioblastoma 
each year in the United States. Approximately two out of three glioblastoma patients will fail 
today’s approved therapies. The tumor grows by changing normal brain cells to stem cell, which 
can continuously replicate and regrow a tumor with only a handful of cells left behind.  In this 
paper we research two different methods to approach the problem. The first method 1) Cloning 
soluble TRAIL into plasmid with hypoxic promoter and transforming into avirulent Salmonella 
Typhimurium for inducing apoptosis in Glioblastoma cells and the second method is 2) To check 
if avirulent Salmonella Typhirium seeks tumors and expresses proteins such as Azurin. This paper 
demonstrates the qualitative results of both. 
Introduction & Background  
The main obstacle faced in treating GBM is in delivery, in that, inconsistency in diffusion gradient 
because of inefficient diffusion through solid tumors. The current treatment option called 
convection enhanced diffusion (CED) tackles this problem by introducing the drug at high pressure 
into the tumor. However this leads to side effects such as inflammation due to the high pressure.  
 
The main principle of this treatment is to deliver a gene drug via a cationic liposomal vector using 
liposomes as vehicles. CED helps to transports particles over long distances creating reasonably 
high tissue concentrations within large volumes. Also, using liposomes as vehicles, instead of viral 
vectors, is a huge advantage. This is because of their uncomplicated preparation and application, 
the lack of immunogenicity and safety requirements, and their comparably long stability at room 
temperature. Safety and efficacy of intracerebrally infused cationic liposome gene constructs have 
been investigated experimentally in vivo and have been chosen for clinical application. However, 
although the method is non-invasive, the process of diffusion has its side-effects. Intracranial 
pressure leads to neural edema, which is inflammation of the brain.8 Further, this method of 
treatment is not efficient either- diffusion does not guarantee uniform distribution or penetration 
of the drug to all affected necrotic regions in the brain. This is also a cause for relapse of the 
glioma.  
 
The other dire problem in the field of anti-cancer drugs is that of clinical attrition. The rates for 
cancer are much higher than those for any other disease because of the complexities involved in 
identifying the correct target using the suitable models. 9 Therefore there is a serious need for 
developing therapies that address all the gaps in the relevant research mentioned above. That is 
how the concept of navigated drug delivery mediated by a molecular ‘vehicle’ has come about. 
This ‘vehicle’ is required to have a) the transporting vehicle (i.e., lipid), b) the loaded cytotoxic 
agent, and c) the “programmable” navigating/targeting agent (i.e., receptor specific ligand) that 
enables the appropriate delivery routes to avoid toxicity on healthy cells. The ineffective 
concentration of the cytotoxic agent, and the “stealth” nanocarriers (biocompatibility polymers, 
i.e., PEG) enhance the short plasma half-life of the drug-loaded transporting vehicle.10 These 
components are imperative in order for the drug to be able to improve the drug’s selective uptake 
of the cytotoxic agent by the tumor cells, not harm healthy cells.  
 
Hence one new potential treatment method that fulfills the purpose of delivery but also overcomes 
the pressure problem of CED is delivery of drug via a nano-carrier such as avirulent ST, which has 
high migratory and invasive potential. 
For the first study, the protein that we are trying to get delivered into the cells-t is the TRAIL 
protein that is Tumor necrosis factor related apoptosis inducing ligand: a member of the tumor 
necrosis factor (TNF) family. It has high selectivity & specificity in targeting cancer cells for 
apoptosis. The only major downside is that many GBM tumors that make them resistant to TRAIL. 
So high concentrations of TRAIL would be required to induce apoptosis. 
For the second study, the objective is to verify if ST is actually tumor seeking and whether or not 
it will express proteins Azurin. Hypoxia is characteristic of necrotic regions in the brain. 
Furthermore, when normal cells start dying, they spill all of their organelles in the region and 
hence, this region becomes rich in “nutrients”. The ST used is made to be immunocompromised, 
that is, it is devoid of its lipid A layer, which is responsible for providing the bacterium with its 
nutrients and purines.  This is done to fulfill the aim of checking whether the bacteria travel to the 
necrotic region. A summary of the he protein, Azurin, are given in Table 1. 
 
                                                                               Figure 1. Azurin 
 
Approved Work Plan 
My work attempts to bridge these gaps, by eliminating as many drawbacks as possible. I begin by 
establishing the prominence of the disease and the causes associated with it. Next, I explain the 
current treatment options and critique them briefly. Finally, I outline my approach to the problem 
and explain how it eliminates the problems with the current treatments 
 
Methods and materials 
Experiment 1) A series of molecular biology laboratory techniques were followed to transform the 
bacteria with the customized vector. Further, the bacteria was inject in Fischer rats, made hosts to 
the U87-MG cancer cell line. The plasmid vector has a secretory signal peptide, 
IgK(Immunoglobulin Kappa), a hypoxic promoter which functions only under hypoxic conditions, 
PfLE(Pyruvate formate-lyase enzyme), the protein of interest,  TRAIL and the probe, GFP(Green 
Fluorescent Protein) so that it fluoresces under a suitable wavelength of light. The GFP is 
downstream of TRAIL to see if the GFP is expressed along with TRAIL After It is activated the 
extrinsic pathway of apoptosis by binding to TRAIL-R1 and/or TRAIL-R2, whereupon the adaptor 
protein Fas-associated death domain(DD) and initiator caspase-8 are recruited to the DD of these 
receptors. Assembly of this so-called death-inducing signaling complex leads to the sequential 
activation of initiator and effector caspases, and ultimately results in apoptotic cell death. 
Experiment 2) A rat model of Fischer Rats was set up, on which in vivo studies were performed. 
A summary of the methods can be found in Table 2. Both, the control group as well as the subject 
group, were developed with GBM. After 10 days, the control group did not receive any drug, the 
IC group of rats received the drug intra-cranially from a hole in the right cortex, and finally, the 
IV group received the drug, injected through their spine, that is, intra-venous. Following this, the 
animals were sacrificed, perfused and then the brains were harvested and coronally sectioned. All 
the sections were made to undergo three different types of staining: 1) Immunohistochemcal 
staining(IHC) , 2) Fluorescence in situ hybridization (FISH) and, 3)Hematoxylin & Eosin stain (H 
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                         Figure 2. Fischer Rat Model for Experiment 2, in vivo studies for cell line 
3RT1RT2A  
Results 
Figure 1 are images to show the MRI slides of the In vitro Results: testing ST with GC PflE-IgK-
TRAIL-GFP plasmid against U87MG-GFP cells. The last image shows the changes in morphology 
of the cells due to VNP plus plasmid. Figure 2 are images to show how the tumor developed inside 
the brains. A lot of heterogeneity as observed- some developed a tumor on the right cortex, some 
on the left and some, in both cortices. Next, Figure 3 shows images after FISH with dyes such as 
DAPI and Texas Red. The 21s chromosome of the bacteria DNA was hybridized by the artificially 
constructed FISH probe. In the images, the blue color represents the necrotic region and the red 
spots represent the bacteria. Therefore, the overlap of blue and red show that bacteria successfully 
reached the necrotic region and hence were actually tumor seeking. Further, Figure 4a and 4b show 
images for IHC. In this staining, we were staining for the hypoxic region with the primary antibody 
anti-Hif1-α raised in rabbit monoclonal IgG Ab from ABCAM-ab51608, and secondary antibody, 
raised in goat and was anti-mouse IgG1(fluoresces under 633nm). The second protein that was 
stained for was Flag, to track Azurin, This was done by primary antibody, anti-FLAG, raised in 
mouse monoclonal antibody IgG1 from SIGMA F 804, and secondary antibody, raised in oat anti-
Rabbit IgG. An overlap of both these images were done and it showed that Azurin was produced 
in the hypoxic regions. Figure 5 shows images after H & E staining. This was done with the 
purpose of getting an overall picture of the tumor with respect to the brain. For these images, since 
the brain was not frozen in para and sucrose, we see lot of open regions due to ice crystal formation. 
The bacteria was not responsible for any activity there. 
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                                       Figure 2. U89-MG tumor development in Fischer Rats 
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                                                             Figure 4a: IHC Imaging, Flag 
                               
                                                              Figure 4b. IHC Imaging, Hif1-α 
 
                                           
FISCHER 21D_IC FISCHER 22D_IV 
FISCHER 21C_IC FISCHER 24C_IV 




             Discussion 
For the first experiment it was successfully shown that sTRAIL protein TRAIL can induce 
apoptosis on U87MG cells lines in vitro. When the VNP cells, which has the soluble 
TRAIL plasmid to the tumor cells, are added, the protein is made by bacteria and secreted. 
Then, TRAIL comes in contact with tumor cells, triggers the apoptosis pathway (similar to 
your schematic on one of the slides). The DNA gets fragmented and the cells begin to die. 
Losing their morphology is the first thing that you can see when apoptosis happens. Next, 
animal studies have to be done to check if TRAIL will induce apoptosis in Glioblastoma 
cells. For the second experiment, S. Typhimurium strain can seek tumors and express 
Azurin in hypoxic regions. The future plan is to try the xenograft model- U87MG cell lines 
in athymic rats and inject ST with TRAIL plasmid. 
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